EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Corticobasal degeneration: An update

Tamás Révész, Andrew J Lees, Huw Morris R

Ideggyógyászati szemle · 2024 · 77 (11-12) · 379-394

DOI: 10.18071/isz.77.0379 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ideggyógyászati szemle, 2024. Verfasst von Tamás Révész und 2 weiteren Autor:innen. Beteiligte Einrichtung: Queen Square Brain Bank for Neurological Disorders. Hauptthemen laut MEDLINE: tau Proteins, Corticobasal Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Corticobasal degeneration (CBD) is one of the primary tauopathies with a disease onset in the 5th to 7th decade. CBD is a progressive condition of unknown aetiology, which is characterised neuropathologically by neuronal loss, astrogliosis and deposition of filamentous tau inclusions, composed entirely of 4-repeat tau isoforms, in neurons and glial cells in cerebral cortical areas, basal ganglia, brainstem and cerebellar nuclei. The term CBD is now a neuropathological diagnostic one and for the canonical clinical syndrome associated with CBD neuropathological changes, the corticobasal syndrome (CBS) term is used. In addition to CBS, the clinical spectrum also includes a behavioural variant of frontotemporal dementia syndrome, speech disorders, Richardson’s syndrome and, rarely, posterior cortical syndrome. In addition to CBD, CBS can also be caused by other pathologies. A number of genetic risk factors of CBD have been identified. As specific biomarkers confirming CBD as the underlying pathology responsible for CBS or other clinical manifestations are still lacking, for a definitive diagnosis of CBD neuropathological investigation is required. Recent cryo-electron microscopic studies have proven that CBD is a distinct tauopathy associated with a unique molecular structure of the tau filaments, which firmly differentiates it from other primary tauopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsCorticobasal DegenerationHumansTauopathiesRisk FactorsNeuronsCerebral CortexFrontotemporal DementiaBiomarkersBasal Ganglia

Stichwörter der Autor:innen

corticobasal degenerationcorticobasal syndrometauopathy

Substanzen

tau ProteinsBiomarkers

Autor:innen und Institutionen

  • Queen Square Brain Bank for Neurological Disorders.
  • Department of Neurodegenerative Disease.
  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.

Zitieren

APA

Révész, T., Lees, A. J., & Morris R, H. (2024). Corticobasal degeneration: An update. Ideggyógyászati szemle, 77(11-12), 379-394. https://doi.org/10.18071/isz.77.0379

Vancouver

Révész T, Lees AJ, Morris R H. Corticobasal degeneration: An update. Ideggyógyászati szemle. 2024;77(11-12):379-394. doi:10.18071/isz.77.0379

BibTeX
@article{Rvsz2024,
  author = {Révész, Tamás and Lees, Andrew J and Morris R, Huw},
  title = {Corticobasal degeneration: An update},
  journal = {Ideggyógyászati szemle},
  year = {2024},
  volume = {77},
  number = {11-12},
  pages = {379--394},
  doi = {10.18071/isz.77.0379}
}
Kostenlos starten →